CJC-1295 + Ipamorelin
GHRH Analog + GH Secretagogue Stack
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The combination has no clinical-outcome RCTs. Component pharmacology is documented only in small phase-1 work: Teichman 2006 (JCEM, n~50 healthy adults) showed CJC-1295 raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold for days, and ipamorelin selectively raised GH in early trials, but the sole controlled phase-2 program for ipamorelin (postoperative ileus, NCT00672074, Helsinn) was discontinued for lack of efficacy. Body-composition, recovery, and sleep claims for the stack rest on mechanism and marketing, not human trials, so the honest grade is 1.
- FDA
- Unapproved; both reviewed by PCAC and recommended against 503A bulks inclusion
- WADA
- Prohibited (S2, Peptide Hormones and GH Secretagogues)
Reference only. Not medical advice.
What can go wrong
No clinical-outcome trials; FDA cited serious safety concerns and adverse events including death across GH-secretagogue studies; chronically elevated IGF-1 associated with cell proliferation; insulin resistance; impurity and immune risk from unregulated compounded/research-chemical product.
Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about CJC-1295 + Ipamorelin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
CJC-1295 extends GHRH half-life for days via albumin-binding DAC technology. Ipamorelin triggers clean, selective growth hormone pulses without the cortisol or hunger spikes of older secretagogues. Used together for body composition. Both were specifically named by the FDA as carrying serious safety risks, an unusual, pointed callout.
The most commercially active unapproved stack, and the most formally flagged by the FDA.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
This is a pairing of two growth-hormone secretagogues that push the pituitary to release more of the body's own growth hormone, rather than injecting growth hormone itself. CJC-1295 mimics growth-hormone-releasing hormone (GHRH) and raises the baseline signal; ipamorelin mimics ghrelin and sharpens the natural pulses through a separate receptor. Hitting both pathways at once produces a larger, still-pulsatile burst of growth hormone than either alone, which in turn raises IGF-1, the downstream hormone behind much of growth hormone's effect on muscle, fat and tissue repair. The selling point is a more natural, rhythmic rise in growth hormone instead of the flat elevation of injected hormone.
CJC-1295 is a synthetic analog of GHRH, about 30 amino acids, developed by ConjuChem in the mid-2000s and originally aimed at HIV-related wasting. It comes in two forms: with DAC (a Drug Affinity Complex that binds albumin for a 6-to-8-day half-life and weekly dosing) and without DAC, known as Mod GRF 1-29, which clears in minutes and is dosed more often. Ipamorelin is a small five-amino-acid peptide and the first selective growth-hormone secretagogue, acting on the ghrelin receptor without stirring cortisol or prolactin, though it contains unnatural amino acids that complicate quality control. The two are combined precisely because they work through different receptors.
- Type
- GH secretagogue pair
- CJC-1295
- GHRH analog
- Ipamorelin
- Ghrelin mimetic
- Dosing
- Weekly (DAC) or daily
- Raises
- GH and IGF-1
- FDA
- Not approved
Higher Hormone, Unproven Payoff
The mechanism here is real, which is exactly why the honesty has to be precise. These peptides do reliably raise growth hormone and IGF-1, and the synergy between a GHRH analog and a ghrelin mimetic has been demonstrated. What has not been demonstrated is that doing so delivers the things people buy them for. There is no good evidence that raising growth hormone this way slows aging, and no long-term human trials show that the combination produces the muscle gain, fat loss or recovery in healthy adults that the marketing promises. Meanwhile the downside is concrete: chronically elevated growth hormone can cause insulin resistance, fluid retention, joint pain and carpal-tunnel symptoms, and the FDA has flagged immunogenicity with a risk of anaphylaxis for both peptides, a cardiovascular vasodilatory reaction for CJC-1295, and deaths associated with intravenous ipamorelin. Raising a hormone is not the same as improving health, and that gap is the whole story.
Safety in detail
Sold as compounded or research-chemical material outside any FDA approval. After the Sept 2024 removal from interim 503A Category 2 and the FDA and PCAC recommendations against inclusion in the 503A bulks list (ipamorelin Oct 29, 2024; CJC-1295 Dec 4, 2024), neither compound is eligible for legal pharmacy compounding for human use, and neither has an approved indication.
- The FDA has flagged immunogenicity for both peptides, with a potential for life-threatening anaphylaxis, and quality-control challenges (ipamorelin contains unnatural amino acids that complicate characterization).
- For CJC-1295 specifically, the FDA noted an increased heart rate and a systemic vasodilatory reaction (flushing, warmth, transient drop in blood pressure).
- The FDA review noted deaths associated with intravenous ipamorelin.
- Sustained high growth hormone can cause insulin resistance and higher blood sugar, fluid retention, joint pain and carpal-tunnel symptoms, and over time acromegaly-like changes.
- Because growth-hormone secretagogues increase cellular replication, they are considered unsafe for anyone with active or prior cancer, with a theoretical recurrence risk.
- Injection-site reactions (pain, swelling, hardness, sometimes hives) are the most common everyday complaint.
- Gray-market vials carry the usual unverified identity, dose and purity risks.
- Both are prohibited in sport at all times under the World Anti-Doping Code.
Children and teenagers
Manipulating the growth-hormone axis in a child is a serious matter that belongs only with a pediatric endocrinologist, using approved growth hormone for a diagnosed deficiency and careful monitoring of growth and puberty. There is no role for gray-market secretagogues in minors: no pediatric data, no approval, and a real risk of interfering with normal development, on top of the immunogenicity and cardiovascular concerns the FDA has raised. Any use of CJC-1295 or ipamorelin in someone under 18 outside specialist endocrine care would be dangerous misuse.
What people get wrong
Often saidIt is just your own growth hormone, so it is safe
ActuallyChronically elevated GH and IGF-1 are established promoters of cell proliferation. "Natural" pathway does not mean "no cancer risk."
Often saidResearch-use-only labeling means it is legal and tested
ActuallyLawyers interviewed by CNN called that labeling an attempt to skirt FDA regulation, not a safety classification.
Who profits, and who pushes back
U.S. FDA
Both ipamorelin and CJC-1295 specifically named as carrying serious safety risks, a callout most unapproved peptides never receive.
Oncology research community
GH and downstream IGF-1 promote cell proliferation. Chronic elevation may accelerate undetected tumors.
CNN Investigation
Vials labeled "research use only" called an attempt to skirt FDA regulations.
Gary Brecka
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Sells both compounds at $350-600/vial. Direct commercial interest. RFK Jr. ally.
RFK Jr.
Promised on Brecka's podcast to end the "war at FDA against peptides."
Andrew Huberman
Discussed for sleep and recovery. General wellness sponsors only.
No approved CJC-1295 or ipamorelin product exists, so the legitimate pharmaceutical value in this family sits with the approved GHRH analog tesamorelin and its maker, not with the combo. The money around CJC-1295 plus ipamorelin is the familiar gray-and-compounding economy: research-peptide vendors selling vials, anti-aging and "hormone optimization" clinics building programs around it, telehealth prescribers, and compounding pharmacies that can prepare it after the 2026 reclassification. It is one of the most heavily marketed peptide stacks, often pitched as a natural alternative to growth hormone, which makes it a reliable revenue line for clinics despite the thin outcome evidence.
Where the research comes from
| Place | Share of published research |
|---|---|
| USA | 44% |
| Canada | 28% |
| Denmark | 16% |
| Other | 12% |
Research published from: Canada, USA, Denmark.
How we got here
A compounded combination of a GHRH analog (CJC-1295, available with or without the drug affinity complex that binds albumin and extends half-life) and a GHRP or ghrelin-mimetic (Ipamorelin, Novo Nordisk's pentapeptide coded NNC 26-0161). The two peptides act on complementary receptor pathways to amplify growth hormone release, and the pairing is marketed by anti-aging and wellness clinics as a growth hormone secretagogue stack.
The family traces to GHRH biology and the first GHRH analog drugs: sermorelin, approved in the 1990s, and later tesamorelin, approved in 2010 for HIV-associated fat accumulation. CJC-1295 was developed by ConjuChem in the mid-2000s, originally for wasting conditions, and never reached approval, while ipamorelin emerged from late-1990s work as the first selective growth-hormone secretagogue. Through the 2010s and 2020s the two were paired and popularized in bodybuilding and anti-aging medicine as a natural growth-hormone strategy. The FDA restricted their compounding in 2023, and the 2026 reclassification reopened it, leaving them widely used but still unproven for their marketed benefits.
- 1990sGHRH-analog drugs emerge; sermorelin approved; ipamorelin identified as the first selective secretagogue.
- Mid-2000sConjuChem develops CJC-1295; Teichman trial shows prolonged GH/IGF-1 elevation.
- 2010Tesamorelin, a related GHRH analog, gains FDA approval for an HIV indication.
- 2010s-2020sThe CJC-1295 plus ipamorelin stack is popularized in bodybuilding and anti-aging medicine.
- 2023FDA restricts compounding of both peptides over safety and quality concerns.
- 2026Reclassification reopens compounding (not approval); marketed benefits remain unproven.
The numbers behind the grade
- Form
- Two-peptide stack
- Pathways
- GHRH + ghrelin
- WADA
- Prohibited (S2)
- FDA
- Not approved
- Drives
- IGF-1
- Approved cousin
- Tesamorelin
The people taking it
The most popular growth-hormone peptide stack in the performance and anti-aging worlds, ubiquitous in clinic menus and online vendor catalogs, and consistently marketed as a natural alternative to injected growth hormone.
The visible user base splits into two familiar groups. One is the bodybuilding and physique world, skewing male, using the combo for lean mass, recovery and fat loss, often alongside other performance compounds. The other is the anti-aging and longevity crowd, frequently in their 40s through 60s, drawn by the idea of restoring youthful growth-hormone levels. Both are served heavily through clinics and online vendors, and as with all gray-market use there is no reliable demographic data on who actually self-administers.
Used worldwide, off-label and gray-market, to raise growth hormone for body composition, recovery, sleep and anti-aging, usually as a combined injection through clinics or self-administration. Prohibited for athletes at all times.
Set against the alternatives
Compared with injecting growth hormone directly, the secretagogue approach is marketed as more natural, preserving the body's pulsatile rhythm and feedback, and avoiding a controlled-substance prescription. But injected growth hormone has far more clinical data, and the secretagogues have none proving they deliver the same benefits. The most important comparison is to tesamorelin, a GHRH analog in the same family that is fully FDA-approved (for HIV-associated fat accumulation) and is the regulated option a clinician can actually point to; sermorelin is another older approved GHRH analog. Within the gray market, ipamorelin is preferred over older secretagogues like GHRP-6 because it does not spike hunger, cortisol or prolactin. Against any of these, the CJC-1295 plus ipamorelin combo wins on popularity and loses on evidence.
What we do not know
- Whether raising growth hormone and IGF-1 this way produces any of the muscle, fat-loss or anti-aging benefits claimed, in proper human trials.
- What the long-term safety is, including cancer and metabolic risks from sustained growth-hormone elevation.
- How real the immunogenicity and cardiovascular signals the FDA flagged turn out to be in everyday use.
- Whether the compounding pathway reopened in 2026 stays open after further review.
- Whether the approved cousin tesamorelin is the more sensible choice for anyone who wants a GHRH analog at all.
What could change
The compounding reviewWhether the 2026 reopening survives further FDA advisory review will shape legal access.Tesamorelin as the regulated pathContinued use of the approved cousin as the evidence-based alternative for those who want a GHRH analog.Real outcome trialsThe missing piece is any rigorous trial testing whether the combo delivers its claimed benefits.Growth-hormone-axis researchOngoing interest in selectively modulating growth hormone for specific medical conditions, distinct from the wellness market.
Legal status
Neither CJC-1295 nor ipamorelin is FDA-approved. Both were placed on the FDA's restricted-compounding list in 2023, then moved back to compounding eligibility in the 2026 reclassification (eligibility is not approval). They remain widely sold as research-use-only chemicals, and both are banned in sport at all times. The regulated alternative in this family is tesamorelin, an approved GHRH analog, which a clinician can prescribe for its actual indication. For confirmed growth-hormone deficiency, the established path is approved growth hormone through an endocrinologist.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
The more accountable route is a compounding pharmacy through a clinic or telehealth prescriber, with physician oversight. The cheaper, riskier route is an online research-chemical vendor selling vials as research-use-only, where an independent certificate of analysis is the only quality check. Anyone wanting a regulated GHRH-analog option should ask a clinician about tesamorelin for its approved use rather than self-sourcing the combo.
Gray-market research vials are inexpensive per milligram, and the combo is often sold as a pre-mixed blend. Clinic-based programs cost far more once consultations, lab work and markups are added, and compounded prescriptions sit in between. As always, the cheapest source is the least accountable, and the apparent savings of a research vial come with unverified content.
Both peptides are predominantly synthesized in China and sold as bulk or finished research vials regardless of the reseller's branding. Identity, dose and purity are not guaranteed in that market, and ipamorelin's unnatural amino acids make impurity testing genuinely harder, so a current third-party certificate of analysis matters and is still no substitute for pharmaceutical-grade manufacturing.
ChinaThe dominant source of both peptides as bulk and finished research vials, synthesized and shipped worldwide.Compounding pharmacies (US)Since the 2026 reclassification reopened compounding eligibility, licensed pharmacies can prepare the peptides with a prescription, a more controlled route than research vials.Anti-aging and wellness clinicsA large clinic channel packages the combo into hormone-optimization programs, sourcing through compounders or, less transparently, vendors.Online research vendorsDirect-to-consumer research-use-only sales, the least accountable and the route with no identity or dose guarantee.
At a glance
- CJC half-life
- ~6-8 days (DAC)
- Ipamorelin
- Selective, no cortisol
- Typical price
- $350-600/vial gray market
- FDA status
- Both specifically named
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about CJC-1295 + Ipamorelin.
Nothing outstanding on this one.
Sources
CJC-1295 single subcutaneous dose raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold for days in healthy adults; half-life 5.8-8.1 days
Teichman SL et al., J Clin Endocrinol Metab, 2006;91(3):799-805 (PMID 16352683)
Full JCEM article of record for the CJC-1295 phase-1 pharmacodynamic study
The Journal of Clinical Endocrinology & Metabolism (Oxford Academic)
Ipamorelin phase-2 trial for postoperative ileus was completed then discontinued for lack of efficacy; sponsor Helsinn
Ipamorelin developed by Novo Nordisk, investigated in phase-2 by Helsinn for postoperative ileus, discontinued for lack of efficacy; selective GH secretagogue with little cortisol/prolactin effect
Ipamorelin, Wikipedia (development and trial history with cited sources)
FDA placed CJC-1295 and ipamorelin among peptides with serious safety concerns; studies of ipamorelin, CJC-1295 and related secretagogues reported adverse events including death; concerns include cardiac events, impurities and immune reactions from compounded product
ProPublica, An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs
FDA removed CJC-1295, ipamorelin and other bulk substances from interim 503A Category 2 effective Sept 27, 2024 after nominations were withdrawn, and set PCAC review dates
PCAC reviewed ipamorelin (Oct 29, 2024) and CJC-1295 (Dec 4, 2024); FDA recommended against and PCAC voted against inclusion in the 503A Bulks Regulation, citing insufficient human safety and efficacy data
Frier Levitt, FDA Peptide Regulation analysis (PCAC votes and 503A status)
FDA 503A bulks nomination docket containing the CJC-1295 / modified GRF and ipamorelin submissions and review materials
Compounded CJC-1295 and ipamorelin remain unapproved and not on the 503A bulks list, leaving them ineligible for legal pharmacy compounding for human use
Holt Law, Deep Dive: Regulatory Status of Popular Compounded Peptides
Chronically elevated GH/IGF-1 signaling is associated with cell proliferation, the basis for the cancer-risk caution
Springfield Physical Therapy & Wellness, CJC-1295 and Ipamorelin: What the Research Says
The studies that matter
Raun et al, Eur J Endocrinology1998
Introduced ipamorelin as the first selective growth-hormone secretagogue, raising GH without cortisol or prolactin.
Bowers, GH-releasing peptides1999
Showed that stimulating the GHRH and ghrelin pathways together produces a synergistic GH response greater than the sum of each, the basis for the combo.
Teichman et al, JCEM2006
Demonstrated that CJC-1295 with DAC produces prolonged elevation of GH and IGF-1 in healthy adults after a single dose.
Outcome trials for the claimed benefitsnone
No long-term human trials show that the combination delivers the muscle, fat-loss, recovery or anti-aging outcomes it is marketed for, or establish its safety for those uses.